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Abstract
Background: Pruritus in patients undergoing hemodialysis is a highly prevalent complication that affects quality of
life. Several medications are currently used for the treatment of uremic pruritus, but these are not satisfactory.
PG102P, which is prepared from Actinidia arguta, has an immune-modulating effect on pruritus. This trial is
designed to assess the antipruritic effect of PG102P compared with placebo.
Methods: This multicenter, randomized, double-blind, placebo-controlled clinical trial will include 80 patients
undergoing hemodialysis. The patients will be randomized in a 1:1 ratio to a treatment group (PG102P 1.5 g/day) or
a control group (placebo). The treatment will last for 8 weeks, followed by a 2-week observational period. During
the observational period, all of the patients will maintain the antipruritic treatment previously used. The primary
endpoint will be measured as the difference in visual analog scale between the groups before and after treatment.
Secondary outcomes include serum levels of total immunoglobulin E, eosinophil cationic protein, potassium,
calcium, phosphorus, intact parathyroid hormone, and blood eosinophil count between weeks 0 and 8. Kidney
Disease and Quality of Life and Beck’s Depression Inventory questionnaires will be conducted. Safety assessments
and any adverse events that occur will also be evaluated.
Discussion: The SNUG is a clinical study that aims to investigate the antipruritic effect of PG102P to ameliorate
itching in patients undergoing hemodialysis.
Trial registration: Clinical Trials.gov, NCT03576235. Registered on 4 July 2018.
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Background
Pruritus is a common and distressing complication in
patients with end-stage renal disease [1, 2]. A global
cross-sectional study in 12 countries with more than 18,
000 patients undergoing hemodialysis (HD) reported
that 42% of patients experienced moderate-to-severe
pruritus [3]. Pruritus is associated with impaired quality
of life, sleep disturbance, depression, and increased risk
of mortality [4].
The pathophysiologic mechanism of pruritus is largely
unclear [5]. However, anemia, hypercalcemia, hyperpho-
sphatemia, secondary hyperparathyroidism, and hyper-
magnesemia are known to be associated with uremic
pruritus [6, 7]. Moreover, more than 60% of patients
undergoing HD who do not have significant metabolic
disorders also suffer from chronic pruritus [8].
A longitudinal study of uremic pruritus reported that
changes in itching intensity more than 20% significantly
improved quality of life in patients with moderate-to-
severe itching symptoms [9]. However, treating patients
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with uremic pruritus is a challenge. Antihistamines, ste-
roids, emollients, and phototherapy are currently used,
but have not been thoroughly investigated. Adequate
skin hydration is the cornerstone of antipruritic treat-
ment because xerosis is common in patients undergoing
HD. In a recent review article, gabapentin is recom-
mended due to consistent successful results in several
clinical trials [10–12], which included only 25 to 34 pa-
tients. In a recent study, oral antihistamines were used
by 57% of clinicians as first-line treatment for uremic
pruritus [13], but were no longer recommended in the
latest reviews [14, 15]. Therefore, a novel therapeutic op-
tion is necessary to ameliorate uremic pruritus.
PG102P, which is prepared from Actinidia arguta,
generally called hardy kiwifruit, contains an orally active
immune-modulating activity through T helper 1/2 path-
ways [16] and by inducing regulatory T cells [17]. It
shows an anti-inflammatory effect in various murine
models, such as atopic dermatitis [18], allergic diarrhea
[19], and asthma [20]. Therefore, we hypothesized that
the immune-modulating property of PG102P would play
a role in controlling itching. In this study (the SNUG
trial) we aim to investigate the antipruritic effect of




This is a multicenter, randomized, double-blind, placebo-
controlled trial in which one group will be treated with
PG102P (1.5 g/day) and the other with a placebo. It is an
investigator-initiated clinical trial. The overall study algo-
rithm is illustrated in Fig. 1. A superiority trial is planned
to test the hypothesis that PG102P is effective in relieving
pruritus for patients with end-stage renal disease undergo-
ing HD. Nine tertiary university hospitals (Seoul National
University Boramae Medical Center, Seoul National Uni-
versity Hospital, Seoul National University Bundang Hos-
pital, Ewha Womans University Mokdong Hospital,
Severance Hospital, Chungnam National University Hos-
pital, Gachon University Gil Medical Center, Kyungpook
National University Hospital, and Dongguk University
Ilsan Hospital) will participate in the trial. It was retro-
spectively registered at http://www.clinical trials.gov/
(NCT03576235). Patients aged over 19 years who have
chronic pruritus despite conventional antipruritic treat-
ment undergoing HD will be screened for the study par-
ticipation. During the study period, antipruritic drugs
which had been started before this study were adminis-
tered in all of the study populations without changing the
dosage of the drugs.
Inclusion criteria
The inclusion criteria include the following:
1. Age over 19 years
2. Patients with adequate HD (a dialysis efficiency
calculator, or Kt/V, score >1.2, 4 h of HD three
times per week).
3. Maintenance patients undergoing HD (>3 months)
with chronic pruritus
4. Mean visual analog scale (VAS) score >4 for the last
5 days in the 14-day preobservation period
5. Participants who were allowed to continue the
antipruritic drug treatment at the same dosage and
administration schedule as used at baseline
throughout the study period
6. Patients who agreed to participate in this trial and
provided written informed consent
Exclusion criteria
The exclusion criteria are outlined below:
1. Intact parathyroid hormone >1000 pg/mL within 1
month
2. Serum potassium >7.0 mg/dL
3. HIV antibody-positive
4. Aspartate transaminase (glutamic oxaloacetic
transaminase) or alanine transaminase (glutamic
pyruvic transaminase) >3 times the upper limit of
normal
5. Scheduled to have kidney transplantation within 3
months
6. Cancer history with current treatment
7. Active infection with current treatment
Fig. 1 Flow chart of the SNUG trial
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8. Current itching with dermatologic diseases other
than uremic pruritus
9. Pregnancy, childbearing potential during the study
period, or breastfeeding
10. Allergy or hypersensitivity reaction to PG102P
11. History of participating in another clinical trial
within 2 months or planning to participate in
another clinical trial
12. Not eligible to participate in this trial as a decision
of the researchers
Randomization
Randomization will be performed by an independent
statistician using a computerized random number gener-
ator through the block randomization method of SAS
9.3 software (SAS Institute, Cary, NC, USA). Eligible
participants will be randomly assigned 1:1 to either a
placebo group or a treatment group. All subjects eligible
for selection/exclusion criteria at visit 2 (baseline visit,
week 0) will be assigned to a group according to the al-
location codes of the blocked randomization method.
Each patient will be given a unique study number. An
independent data manager who is not involved with the
clinical practice or patient recruitment will create the
randomization sequence. The practitioners, participants,
outcome assessors, and statisticians will be kept blinded
to treatment allocation throughout the trial. The
randomization lists will be computer-generated and con-
cealed from the investigators by an independent data
manager not involved in the study. This information will
remain confidential and will not be available to the re-
searchers. In this trial, emergent unblinding is not
applicable.
Follow-up
The participants will visit the hospital seven times dur-
ing the study: a screening visit (visit 1), visits during ac-
tive treatment (visits 2, 3, 4, and 5), and a follow-up visit
(visit 6). Each interval between visits is 2 weeks, except
that between visits 4 and 5 (which is 4 weeks).
Primary endpoint and measurement of itch
The primary endpoint is the change in VAS between
visit 2 (week 0) and visits 3, 4, 5, and 6 (weeks 2, 4, 8,
10)—VAS change from baseline.
Itch severity will be measured by the patients using a
VAS. A VAS consisting of a 10-cm horizontal line with
1-cm scale markings will be used. The patients will be
asked to mark the intensity of their itch on the scale,
with the strongest possible itch marked at the right end
of the line (10 cm) and no itch marked at the left end (0
cm). The patients will be asked to mark the VAS value
to record the worst degree of itch experienced during
the previous day. Patients with an average VAS value of
4 or more for 5 consecutive days before visit 2 (week 0)
will be enrolled. The average value of VAS measured 3
consecutive days before each visit (visits 3 to 7) will be
used to evaluate itching.
Secondary and other endpoints
Total immunoglobulin E, eosinophil count, eosinophil
cationic protein, phosphorus, calcium/potassium, intact
parathyroid hormone, Kidney Disease Quality of Life,
and Beck Depression Inventory will also be assessed be-
tween week 0 and week 8.
Clinical and laboratory evaluations
Physical examination, comorbidity, and medication will
be reviewed. Laboratory evaluations, including complete
blood cell count, serum glucose, uric acid, total protein,
albumin, total bilirubin, aspartate transaminase, alanine
transaminase, alkaline phosphatase, blood urea, creatin-
ine, total cholesterol, urinalysis, urine human chorionic
gonadotrophin, and HIV status, will also be performed
at visit 1.
Safety assessment and adverse events
Information on adverse events (AEs) will be obtained
through nondirective questioning to every participant at
each visit. The safety assessments include laboratory
tests (hematology/blood chemistry, urinalysis), electro-
cardiogram, chest x-ray, physical examination, blood
pressure, pulse rate, and changes in body weight. At
least once after randomization, any AEs that occur after
administration of the investigational drug will be
assessed. All AEs will be summarized and presented with
regard to severity, relationship to the investigational
drug, and outcome. The schedule of enrollment, inter-
ventions, and assessments is presented in Fig. 2.
Sample size calculations
The enrolled participants will be randomly divided into
two groups by at a 1:1 ratio. Under the assumption of
2.1 cm (with a pooled standard deviation of 2.4 cm) in
the mean change difference in VAS values between the
PG102P and placebo groups in a preceding pilot study
with 0.9 of power, two-sided, and 0.05 of alpha, 28 par-
ticipants will be allocated to each group. Considering a
dropout rate of 30%, 80 participants will be needed (40
participants per group).
Data collection and management
All data will be recorded by trained clinical investigators
from each participating hospital in a standardized elec-
tronic case report form using a web-based database
(Bethesdasoft Co., Ltd., http://www.mytrial.co.kr). Data
will be handled confidentially and anonymously by quali-
fied data managers. Quality control will involve
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Fig. 2 Timeline of study procedures and outcome assessments. BDI Beck Depression Inventory, Ca calcium, ECG electrocardiogram, ECP
eosinophilic cationic protein, IgE immunoglobulin E, iPTH intact parathyroid hormone, K potassium, KDQoL Kidney Disease Quality of Life, P
phosphorus, VAS visual analog scale
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collecting data on adherence to the intervention, patient
inclusion and follow-up, as well as monitoring the qual-
ity of the data entry. Missing data or inconsistencies in
the data will be detected by programs, and the results
will be reported back to the investigator for resolution. If
any given case is missing a main variable, the results of
the closest observation are carried forward to the ab-
sence of the test data (last observation carried forward).
Through this iterative process, we will clean the data
and finally perform a database lock. All database
backups of the electronic case report form will be done
in real time.
Statistical analyses
Three analysis sets will be used for analyzing data. First,
a safety analysis set will be applied to analyze safety
evaluation parameters. Safety analysis will be performed
for a group of subjects who have ingested at least one
treatment after random assignment. Second, a full ana-
lysis set will be applied, which refers to the ideal set of
subjects as close as possible to the principle of
intentionality analysis (including all of the subjects ran-
domized to enroll and receive at least one treatment).
Third, a per-protocol set will be applied when all of the
factors are in accordance with the research plan; patients
show good compliance using 80–120% of the prescribed
dose. All of the baseline variables must be available, and
there must be no major violation of the test plan.
For the primary endpoint, the degree of change of the
VAS averaged after treatment from baseline will be ana-
lyzed using the paired t test or Wilcoxon signed rank
test in each group. The difference between the groups
will be analyzed with the two-sample t test or Wilcoxon
rank sum test. Additionally, an analysis of covariance
will be conducted with adjustments for covariates. Simi-
lar to the primary endpoint, the same analyses will be
performed for the secondary endpoints. For categorical
variables, the McNemar test will be carried out to evalu-
ate the change from baseline in each group.
Demographic and clinical characteristics will be re-
ported in terms of mean ± standard deviation for con-
tinuous variables, or as frequencies and percentages for
categorical variables. Differences between groups will be
analyzed using the two-sample t test or Wilcoxon rank
sum test for continuous variables and the χ2 test or Fish-
er’s exact test for categorical variables.
AEs and adverse drug reactions will be tabulated for
each treatment group in accordance with the system
organ class and preferred terms of the Medical Diction-
ary for Regulatory Activities. The AEs and adverse drug
reactions will then be classified according to severity,
seriousness, and causal relationship to the study drug.
Intergroup comparisons will be conducted using the χ2
test or Fisher’s exact test.
A value of P < 0.05 will be considered statistically sig-
nificant. All analyses will be performed using SPSS Sta-
tistics software (v21.0; IBM Corporation, Armonk, NY,
USA).
Discussion
This study will compare the changes in VAS between
the PG102P and placebo groups in patients with uremic
pruritus undergoing HD. The aim of PG102P treatment
is to alleviate the itching sensation to improve the qual-
ity of life, including improving depression, insomnia, and
ultimately the risk of mortality of patients.
Novel antipruritic drug development and research are
actively ongoing. Naltrexone, a μ-opioid receptor antag-
onist, was investigated in a randomized control trial
(RCT), but showed no effect and was accompanied by a
high incidence of gastrointestinal side effects [21].
Nalfurafine, a κ-opioid receptor agonist, has been re-
cently proven to effectively reduce itches that were re-
fractory to current treatments with few significant
adverse reactions in an RCT with 337 patients undergo-
ing HD [22]. Nalfurafine was approved for clinical use
by the Ministry of Health, Labour and Welfare of Japan
in 2009. Nalfurafine seems to be potent, but it is expen-
sive and currently prescribed only in Japan [13].
Pregabalin was examined in an RCT with 179 patients
undergoing HD and was found to reduce VAS for prur-
itus by 6.6 cm at 12 weeks after starting the drug [23].
This reduction is remarkably larger than that seen with
nalfurafine (4.2 cm at week 24 and 4.4 cm at week 52). A
large-scale RCT is warranted in the future for validation.
PG102P is a water-soluble extract prepared from the
edible fruit of A. arguta; therefore, safety problems are
not an issue. A previous toxicity study showed that
PG102P is a safe agent [16]. Moreover, in an RCT with
90 asymptomatic atopic dermatitis patients in 2011, no
serious AEs were observed [24]. PG102P is also
inexpensive.
We introduced VAS as a monodimensional scale for
assessing pruritus intensity [25]. It is a simple method
and has been validated in large-scale studies consisting
of chronic pruritus patients, especially in RCTs of pa-
tients with uremic pruritus [10, 21–23]. It is highly re-
producible and shows great correlation between scales.
However, a VAS only provides the itch intensity at a
specific point in time, and is susceptible to cofounding
factors such as current mood, stress and comorbidities.
Multidimensional scales, such as the Itch Severity Scale
[26], a self-reported seven-item scale, are an alternative
method. They provide comprehensive scores of itch in-
tensity, sleep disturbance and burden by the symptom,
but are not established in clinical practice.
Although we calculated the adequate sample size, the
absolute number is quite small. The sample could
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potentially include relatively homogeneous patients so
there might be a limitation in generalizing the results of
our RCT to entire HD patient populations. Compared
with cross-sectional designs, repeated measures designs
allow the definitive evaluation of within-person changes
over time and have higher statistical power for detecting
differences. Thus, fewer participants are required for
conducting a study. Most of the RCTs on uremic prur-
itus have traditionally used repeated measures designs
[27].
In summary, the SNUG study is a multicenter, ran-
domized, double-blind, placebo-controlled clinical trial
that will evaluate the efficacy and safety of PG102P ver-
sus placebo in patients with chronic pruritus undergoing
HD. This study is expected to confirm whether PG102P
has an antipruritic effect.
Trial status
Patient recruitment began on 1 May 2018. At the time
of manuscript submission, 45 patients had been re-
cruited, and recruitment will be completed by 31 De-
cember 2018.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3753-1.
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